Biomarin Pharmaceutical (BMRN) Acquisitions (2009 - 2016)

Biomarin Pharmaceutical (BMRN) posted Acquisitions of $1.3 million for Q4 2016, down 99.75% on a QoQ basis from $538.4 million in Q1 2015.

Biomarin Pharmaceutical (BMRN) Acquisitions (2009 - 2016) Analysis & Trends

Biomarin Pharmaceutical's Acquisitions history runs 5 years deep, the most recent figure standing at $1.3 million for Q4 2016.

Quarterly Acquisitions changed N/A year-over-year to $1.3 million in Q4 2016, while the trailing twelve-month figure through Dec 2017 was $1.3 million (changed 0.0% YoY) and the FY2016 annual result came in at $2.8 million, down 99.48% from the prior year.
Acquisitions was $1.3 million for Q4 2016 at Biomarin Pharmaceutical, down from $538.4 million in the prior quarter.
Across five years, Acquisitions topped out at $538.4 million in Q1 2015 and bottomed at $1.3 million in Q4 2016.
A 3-year average of $183.2 million and a median of $9.9 million in 2013 frame the typical range for Acquisitions.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Acquisitions (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	-
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Biomarin Pharmaceutical	11.33 Bn	9.11 Bn	571.21 Mn	-

Download Data